Gain Therapeutics, Inc. - GANX STOCK NEWS

Gain Therapeutics, Inc. (Nasdaq: GANX) is set to present at the Jefferies Healthcare Conference from June 8-10, 2022, in New York, NY. COO Matthias Alder will host a corporate presentation on June 10 at 8:00 AM ET, with a live webcast available on the company's website. Gain Therapeutics focuses on transforming drug discovery through its proprietary technology, SEE-Tx®, which identifies novel allosteric binding sites for various diseases. Their pipeline targets neurodegenerative diseases, lysosomal storage disorders, and oncology, with significant funding support for their Parkinson’s disease program.

Gain Therapeutics, Inc. (Nasdaq: GANX) will present at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 1:30 PM ET. CEO Eric Richman is set to lead the corporate presentation and host one-on-one meetings during the event, which runs from May 23-25 in Miami, Florida. Gain is known for its innovative drug discovery platform that targets allosteric binding sites to create small molecule treatments for various diseases, including neurodegenerative disorders. A live webcast will be available on their website, and an archived version will follow.

Gain Therapeutics (GANX) reported a net loss of $3.27 million for Q1 2022, improving from a loss of $2.54 million in Q1 2021. Revenue increased to $45,000, driven by collaboration agreements. R&D expenses rose to $1.56 million, while general and administrative costs surged to $1.78 million. The company holds $34.34 million in cash, providing operational runway into the latter half of 2023. Notable preclinical data was presented for its lead candidate GT-02287 targeting Parkinson’s and Gaucher's diseases, suggesting its potential therapeutic benefits.

Gain Therapeutics (Nasdaq: GANX) showcased promising data for its lead compound GT-02329 targeting Gaucher disease at the 1st IWGDD Symposium. The compound boosts GCase levels and activity, effectively reducing toxic substrate accumulation in both human and mouse models. Specifically, the data highlighted increased GCase activity and decreases in glucosylceramide (GlcCer) and glucosylsphingosine (GlcSph). The company aims to further investigate GT-02329's potential as a therapy to alleviate neurological effects associated with Gaucher disease.

Gain Therapeutics, Inc. (Nasdaq: GANX) has announced promising pre-clinical results for its lead compound, GT-02287, targeting Parkinson’s Disease. Presented at the XXVII World Congress on Parkinson’s Disease, the compound successfully penetrates the brain, reduces alpha-synuclein levels, and improves dopamine production in neuronal models. Data showcases its ability to bind with the GCase protein, enhancing lysosomal function. The findings suggest potential disease-modifying effects, positioning GT-02287 as a candidate for clinical advancement this year.

Gain Therapeutics (Nasdaq: GANX) announced that CEO Eric Richman will participate in a fireside chat at the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference on April 28, 2022, from 2:00 to 2:30 p.m. ET. Investors are invited to join via webcast. Gain Therapeutics specializes in drug discovery using its proprietary computational platform, SEE-Tx®, targeting allosteric regulators for various diseases. The company’s lead program focuses on Parkinson’s disease, supported by funding from notable organizations.

Gain Therapeutics (Nasdaq: GANX) presented promising pre-clinical data for its lead candidate GT-02287 at the 2022 Synuclein Meeting in Belgium. The compound enhances GCase levels, promotes lysosomal health, and depletes alpha-synuclein, indicating potential benefits for Parkinson's Disease patients. Key findings include increased GCase activity and neuron survival in relevant models. CEO Eric Richman emphasized the candidate's disease-modifying potential, while the data supports a therapeutic strategy targeting GCase for neurodegenerative diseases.

Gain Therapeutics (Nasdaq: GANX) announced promising pre-clinical data for its Gaucher Disease program, presented at the 2022 Glycolipid and Sphingolipid Biology GRC. The study highlighted that lead compounds significantly increase the levels and activity of the beta-glucocerebrosidase (GCase) protein, enhancing its co-localization with lysosomes and reducing toxic substrate accumulation in neurons. These orally bioavailable compounds may offer a potential treatment for patients with neuronopathic Gaucher disease, addressing a significant unmet medical need.

Gain Therapeutics, Inc. (Nasdaq: GANX) announced significant progress in its lead program for GBA1 Parkinson’s Disease, highlighted by compelling preclinical data and a strong cash position of $36.88 million as of December 31, 2021. The company plans to initiate a first-in-human clinical trial by the end of 2022, following their collaboration with Zentalis Pharmaceuticals to identify novel oncology molecules. Despite increased operating expenses leading to a net loss of $13.89 million, the increase in revenue to $165,000 indicates growing traction in their development efforts.